Evaluation of single maintenance and reliever therapy (SMART) prescribing of budesonide‐formoterol for asthma after a clinical pharmacist‐led initiative

• Published in: JAACP : Journal of the American College of Clinical Pharmacy 2024-03, Vol.7 (3), p.215-223
• Main Authors: Harris, Ila M., Philbrick, Ann M., Klemenhagen, Kristen C.
• Format: Article
• Language: English
• Subjects: asthma; family practice; pharmacists; prescriptions; treatment switching
• ISSN: 2574-9870; 2574-9870
• DOI: 10.1002/jac5.1922

Introduction Single maintenance and reliever therapy (SMART) with a combination inhaled corticosteroid‐formoterol inhaler is the preferred asthma treatment by the Global Initiative for Asthma and the National Asthma Education and Prevention Program guidelines. These recommendations have been slow to be implemented routinely into clinical practice. Methods This was an observational cohort study conducted in a family medicine residency program clinic. A clinical pharmacist‐led initiative to implement SMART, which included provider education and the development of clinical tools to facilitate SMART prescribing, was assessed. Year 1 (Y1; pre‐intervention) and year 2 (Y2; post‐intervention) were compared. Outcomes The primary outcome was to evaluate the impact of this initiative on the frequency of SMART (budesonide‐formoterol without albuterol) prescribing. Prescription frequencies for albuterol and budesonide‐formoterol were also compared separately. Secondary outcomes were Asthma Control Test (ACT) scores and prescribing frequencies among faculty and resident physicians. Results The total number of eligible patients in the clinic population was 807, and 459 of these patients met the inclusion criteria. There were more females than males, and the mean age was 39. About 24% had a language preference other than English and 22% required an interpreter. The percentage of patients who were prescribed SMART significantly increased from 0.44% to 11.5% (p